Effects of Transcutol P and Precirol ATO-5 on Percutaneous Absorption of Flutamide from Emulgels

The research paper discusses the effects of Transcutol P and Precirol ATO-5 on the percutaneous absorption of Flutamide from emulgels. Flutamide is a non-steroidal anti-androgenic agent used in treating prostate cancer and disorders like androgenic alopecia and male pattern baldness. The study found that the percutaneous absorption of flutamide emulgels formulated with these enhancers was higher than control formulations. The enhancement ratio increased from 1.218 to 3.670 and 1.346 to 3.900 for Precirol ATO5 and Transcutol P, respectively. The area under the Curve (AUC) increased with the enhancers’ concentration, with a significant upsurge seen at the 1% concentration for both enhancers. The study concluded that the flutamide emulgel containing 1% Transcutol P showed more appropriate percutaneous absorption through the skin compared to others.